Patient case: Impact of smoking cessation on international normalized ratio

Journal of Pharmacy Practice

Volumn 27, Issue 5, 2014, Pages 470-473

  Jordan, Shane D ^a   Stone, Mark D ^b   Alexander, Earnest ^a   Haley, Joseph ^a   McKee, Albert ^a  

^a TAMPA GENERAL HOSPITAL   (United States)

^b Bayfront Medical Center   (United States)

Author keywords

international normalized ratio; smoking cessation; warfarin

Indexed keywords

CYCLOBENZAPRINE; LISINOPRIL; PHENYTOIN; SALBUTAMOL; TADALAFIL; WARFARIN; ANTICOAGULANT AGENT;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CASE REPORT; DEEP VEIN THROMBOSIS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FOLLOW UP; HEALTH IMPACT ASSESSMENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIFESTYLE MODIFICATION; MALE; MIDDLE AGED; SMOKING CESSATION; SMOKING HABIT; TREATMENT DURATION; DOSE RESPONSE; DRUG INTERACTION; METABOLISM; SMOKING; VENOUS THROMBOSIS;

ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; SMOKING; SMOKING CESSATION; VENOUS THROMBOSIS; WARFARIN;

EID: 84908870797     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190013516501     Document Type: Article

References (13)

1. Stahmann MA, Huebner CF, Link KP. Studies on the hemorrhagic sweet clover disease. Identification and synthesis of the hemorrhagic agent. J Biol Chem. 1941 ; 138: 513-527
2. Kroon LA. Drug interactions with smoking. Am J Health Syst Pharm. 2007 ; 64 (18). 1917-1921
3. Nathisuwan S, Dilokthornsakul P, Chaiyakunapruk N, et al. Assessing evidence of interaction between smoking and warfarin: a systematic review and meta-analysis. Chest. 2011 ; 139 (5). 1130-1139
4. Turkoski BB. Induction or inhibition: the complexity of cytochrome P450 enzymes and their impact on drug interactions. Orthop Nurs. 2002 ; 21 (3). 68-73
5. Correia MA Drug biotransformation. Chapter 4. Basic & Clinical Pharmacology. New York: Lange Medical /McGraw-Hill ; 2012:
6. Zevin S, Benowitz NL. Drug Interactions with Tobacco Smoking. Clinal Pharmacokinet.. 1999 ; 36 (6). 425-438
7. Hoffmann D, Djordjevic MV, Hoffmann I. The changing cigarette. Prev Med. 1997 ; 26 (4). 427-434
8. Olson R, Shils ME, Olson JA, et al Modern nutrition in health and disease. 8th ed. Volume 1. Philadelphia: Lea & Febiger ; 1994: 342-357.
9. Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharm Ther. 2004 ; 76 (2). 178-184
10. Bachmann K, Shapiro R, Fulton R, Carrol FT, Sullivan TJ. Smoking and warfarin disposition. Clin Pharmacol Ther. 1979 ; 25 (3). 309-315
11. Terziivanov D, Bozhinova K, Dimitrova V, et al. Nonparametric expectation maximisation (NPEM) population pharmacokinetic analysis of caffeine disposition from sparse data in adult caucasians systemic caffeine clearance as a biomarker for cytochrome P450 1A2 activity. Clin Pharmacokinet. 2003 ; 42 (15). 1393-1409
12. Colucci VJ, Knapp JF. Increase in international normalized ratio associated with smoking cessation. Ann Pharmacother. 2001 ; 35 (3). 385-386
13. Evans M, Lewis GM. Increase in international normalized ratio after smoking cessation in a patient receiving warfarin. Pharmacotherapy. 2005 ; 25 (11). 1656-1659